Skip to main content

Table 2 Treatment efficacy and subgroup analysis

From: Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial

Variable N Overall response rate (%) P-value Median progression-free survival (months) [95%CI] Log-rank P-value Hazard ratio for PFS [95% confidence interval] Median overall survival (months) [95%CI] Log-rank P-value Hazard ratio for OS [95% confidence interval]
Whole group 84 52.4   7.9[6.6–9.2]    25.8[20.4–31.1]   
Lines of chemotherapy    0.044*   0.001* 2.2[1.3-3.6]   0.000* 3.8[2.0-7.2]
 First-line 59 65.4   9.4[6.5–12.3]    Not reached   
 Second-line or more 25 38.0   5.7[4.3–7.2]    14.9[7.5–22.2]   
Molecular subtypes    0.144   0.102 n.s.   0.08 n.s.
 Luminal 61 54.4   8.2[6.8–9.5]    22.1[14.7–29.5]   
 HER2 positive 10 87.5   10.5[7.3–13.5]    Not reached   
 Triple-negative 12 50.0   5.1[4.3–5.9]    15.7[2.5–29.0]   
Prior taxane    0.429   0.007* 1.9[1.1-3.1]   0.002* n.s.
 Yes 55 47.3   6.9[5.1–8.6]    21.8[16.7–27.0]   
 No 29 62.0   10.7[10.1–11.3]    Not reached   
Liver metastasis    0.017*   0.062 n.s.   0.028* 3.7[1.5-8.8].
 Yes 48 46.7   6.8[5.4–8.1]    21.8[16.9–27.1]   
 No 36 74.2   8.6[5.6–11.6]    Not reached   
Overall response     0.000* n.s.   0.007* n.s.
 ORR 44   10.4[8.0–12.8]    Not reached   
 Non-ORR 32   4.8[2.8–6.8]    21.8[14.9–28.8]   
  1. * P<0.05,statistical significance